Panel Backs FDA Plan To Expand KASA Platform To New Drugs, Biologics

By Beth Wang / November 4, 2022 at 3:46 PM

A panel of FDA advisers unanimously supported the agency’s plan to expand its generic drug quality review platform to also include new drugs, biologics and post-approval changes over the next five years.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.